Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer

…, E von Witting, J Garousi, R Zelchan… - Journal of nuclear …, 2021 - Soc Nuclear Med
Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may help to stratify breast and gastroesophageal cancer patients for HER2-…

Phase I trial of 99mTc-(HE) 3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer

…, L Tashireva, J Sörensen, R Zelchan… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Radionuclide molecular imaging of human epidermal growth factor receptor type 2 (HER2)
expression may enable a noninvasive discrimination between HER2-positive and HER2-…

[HTML][HTML] Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging …

V Chernov, A Rybina, R Zelchan, A Medvedeva… - Cancers, 2023 - mdpi.com
Simple Summary Prostate and breast cancers are the most common malignancies. Accurate
diagnosis and staging of diseases are important for the prognosis and determination of …

Experimental study of 99mTc-aluminum oxide use for sentinel lymph nodes detection

VI Chernov, IG Sinilkin, RV Zelchan… - AIP conference …, 2016 - pubs.aip.org
The purpose of the study was a comparative research in the possibility of using the
radiopharmaceuticals 99mTc-Al2O3 and 99mTc-Nanocis for visualizing sentinel lymph nodes. The …

[HTML][HTML] Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in …

…, M Tretyakova, F Yuldasheva, R Zelchan… - International Journal of …, 2022 - mdpi.com
Non-invasive radionuclide imaging of human epidermal growth factor receptor type 2 (HER2)
expression in breast, gastroesophageal, and ovarian cancers may stratify patients for …

[HTML][HTML] Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer

…, V Chernov, M Larkina, A Rybina, R Zelchan… - Theranostics, 2023 - ncbi.nlm.nih.gov
The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is
of increasing importance with the recent approval of more efficacious HER2-targeted …

[HTML][HTML] The first experience of using 99mTc-1-thio-d-glucose for single-photon emission computed tomography imaging of lymphomas

VI Chernov, EA Dudnikova, RV Zelchan… - Siberian Journal of …, 2018 - siboncoj.ru
Introduction. The purpose of this study was to evaluate the feasibility of using 99mTc-TG
SPECT in the detection and staging of malignant lymphoma. Materials and methods. Fifteen …

[HTML][HTML] The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

…, J Borin, F Lundmark, A Rybina, S Hober, R Zelchan… - Diagnostics, 2023 - mdpi.com
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in the majority of primary
prostate tumors and in prostatic lymph node and bone metastases. Several GRPR antagonists …

[HTML][HTML] 99mTc-labeled monosaccharide kits: development methods and quality control

E Stasyuk, V Sкuridin, A Rogov, R Zelchan, V Sadkin… - Scientific Reports, 2020 - nature.com
The paper presents the procedure for planning an experiment to create standard sets of
reagents for a technetium-99m generator based on glucose derivatives. All stages are …

[HTML][HTML] 99mTc-labeled nanocolloid drugs: development methods

…, E Stasyuk, A Rogov, N Varlamova, R Zelchan - Scientific Reports, 2020 - nature.com
The work considers the problem of obtaining nanocolloid radiopharmaceuticals (RPs) and
studying their functional suitability for diagnosing sentinel lymph nodes (SLN) in cancer …